Daiichi Sankyo H1 Profit Climbs 16% on Enhertu, Datroway Growth; Maintains FY26 Guidance

Daiichi Sankyo Co., Ltd. (DSKYF) reported first-half profit attributable to owners rose 15.8% to JPY151.534 billion for the six months ended September 30, 2026, up from JPY130.814 billion a year earlier, as cancer drugs Enhertu and Datroway drove revenue growth. The company maintained its full-year forecasts. Revenue climbed 19.7% to JPY1,167.233 billion from JPY975.353 billion, including a JPY73.9 billion benefit from the weaker yen. Enhertu revenue, including milestone payments, advanced 51.4% to JPY500.0 billion, while Datroway revenue rose 161.6% to JPY54.4 billion. Operating profit increased 34.4% to JPY193.795 billion. For the year ending March 31, 2027, Daiichi Sankyo kept revenue guidance of JPY2,340 billion, operating profit of JPY320 billion and core operating profit of JPY360 billion. Profit attributable to owners is projected at JPY251 billion. The stock was trading up 4.28% at JPY2,729 on the Tokyo Stock Exchange.